Progression-free survival of early interim PET-positive patients with advanced stage Hodgkins lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann, P; Haverkamp, H; Lohri, A; Mey, U; Kreissl, S; Greil, R; Markova, J; Feuring-Buske, M; Meissner, J; Dührsen, U; Ostermann, H; Keller, U; Maschmeyer, G; Kuhnert, G; Dietlein, M; Kobe, C; Eich, H; Baues, C; Stein, H; Fuchs, M; Diehl, V; Engert, A; Lancet Oncol. 2017; 18(4): 454-463.

Antiangiogenic therapy in breast cancer.

Gampenrieder, SP; Westphal, T; Greil, R; Memo. 2017; 10(4):194-201

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group.

Engert, A; Goergen, H; Markova, J; Pabst, T; Meissner, J; Zijlstra, JM; Král, Z; Eichenauer, DA; Soekler, M; Greil, R; Kreissl, S; Scheuvens, R; Eich, H; Kobe, C; Dietlein, M; Stein, H; Fuchs, M; Diehl, V; Borchmann, P; Hemasphere. 2017; 1(1): e5

Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy – an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial

Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Bergh, J; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF; Gnant, M J BONE MINER RES. 2018; 33: 55-55.

Elucidating the contribution of AID to the clonal evolution of chronic lymphocytic leukemia

Schubert, M; Zaborsky, N; Huemer, M; Hopner, JP; Gassner, FJ; Arzt, C; Greil, R; Geisberger, R ONCOL RES TREAT. 2018; 41: 169-169.

Subgroup analysis in elderly patients with metastatic pancreatic cancer: Preliminary results of Austrian real world data with nab-paclitaxel/gemcitabine

Prager, G; Gerger, A; Eisterer, W; Mlineritsch, B; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubman, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Woll, E; Neumann, H; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Grunberger, B; Ohler, L ONCOL RES TREAT. 2018; 41: 125-126.

Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)

Rummel, M; Buske, C; Hertenstein, B; Lerchenmuller, CA; Koenigsmann, M; Lange, E; Reeb, M; Kaiser, U; Balser, C; Behringer, D; Durig, J; Gaska, T; Maschmeyer, G; Schliesser, G; Burchardt, A; Barth, J; Kauff, F; Hinke, A; Greil, R ONCOL RES TREAT. 2018; 41: 251-251.

Screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer. AGMT Gastric-5

Woll, E; Regitnig, P; Winder, T; Thaler, J; Hockl, P; Eisterer, W; Ganzer, H; Wustner, A; Andel, J; Greil, R ONCOL RES TREAT. 2018; 41: 255-255.

The HIV continuum of care in Austria from 2010 to 2016: data and challenges

Leierer, G; van Sighem, A; Rieger, A; Schmied, B; Sarcletti, M; Ollinger, A; Haas, B; Egle, A; Rappold, M; Zangerle, R J INT AIDS SOC. 2018; 21:

Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer

Steger, G; Petru, E; Haslbauer, F; Marth, C; Egle, D; Galid, A; Sliwa, T; Lang, A; Kuehr, T; Petzer, A; Ruckser, R; Greil, R; Mlineritsch, B; Singer, C; Seifert, M; Andel, J; Kwasny, W; Pichler, P; Tinchon, C; Bartsch, R EUR J CANCER. 2018; 92: S97-S97.